Matteo Maria Naldini
Overview
Explore the profile of Matteo Maria Naldini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Notini G, Naldini M, Sica L, Viale G, Rognone A, Zambelli S, et al.
Front Oncol
. 2024 Mar;
14:1374547.
PMID: 38529378
Background: Nausea and vomiting are common side effects of Trastuzumab Deruxtecan (T-DXd), but guidelines for optimal management were not initially available. This retrospective single-center study aimed at evaluating the efficacy...
2.
Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis
Quaranta P, Basso-Ricci L, Hernandez R, Pacini G, Naldini M, Barcella M, et al.
Blood
. 2024 Mar;
143(19):1937-1952.
PMID: 38446574
In physiological conditions, few circulating hematopoietic stem/progenitor cells (cHSPCs) are present in the peripheral blood, but their contribution to human hematopoiesis remain unsolved. By integrating advanced immunophenotyping, single-cell transcriptional and...
3.
Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D, et al.
Nat Biotechnol
. 2024 Jan;
42(6):986.
PMID: 38273067
No abstract available.
4.
Venanzi F, Bini M, Nuccio A, De Toma A, Lambertini M, Ogliari F, et al.
Cancer Treat Rev
. 2023 Nov;
121:102648.
PMID: 37918169
In the immunoncology era, growing evidence has shown a clear sex dimorphism in antitumor immune response with a potential impact on outcomes upon immunecheckpoint blockade (ICI) in patients with cancer....
5.
Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D, et al.
Nat Biotechnol
. 2023 Sep;
42(6):877-891.
PMID: 37679541
Base and prime editors (BEs and PEs) may provide more precise genetic engineering than nuclease-based approaches because they bypass the dependence on DNA double-strand breaks. However, little is known about...
6.
Caserta C, Nucera S, Barcella M, Fazio G, Naldini M, Pagani R, et al.
Leukemia
. 2023 Aug;
37(10):1994-2005.
PMID: 37640845
Complete elimination of B-cell acute lymphoblastic leukemia (B-ALL) by a risk-adapted primary treatment approach remains a clinical key objective, which fails in up to a third of patients. Recent evidence...
7.
Licata L, Mariani M, Rossari F, Viale G, Notini G, Naldini M, et al.
Breast
. 2023 Apr;
69:330-341.
PMID: 37003065
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive...
8.
Naldini M, Casirati G, Barcella M, Rancoita P, Cosentino A, Caserta C, et al.
Nat Commun
. 2023 Mar;
14(1):1285.
PMID: 36890137
Acute myeloid leukemia may be characterized by a fraction of leukemia stem cells (LSCs) that sustain disease propagation eventually leading to relapse. Yet, the contribution of LSCs to early therapy...
9.
Montaldo E, Lusito E, Bianchessi V, Caronni N, Scala S, Basso-Ricci L, et al.
Nat Immunol
. 2022 Sep;
23(10):1470-1483.
PMID: 36138183
Traditionally viewed as poorly plastic, neutrophils are now recognized as functionally diverse; however, the extent and determinants of neutrophil heterogeneity in humans remain unclear. We performed a comprehensive immunophenotypic and...
10.
Levi R, Carli F, Arevalo A, Altinel Y, Stein D, Naldini M, et al.
BMJ Health Care Inform
. 2021 Jan;
28(1).
PMID: 33455913
Objective: Gastrointestinal (GI) bleeding commonly requires intensive care unit (ICU) in cases of potentialhaemodynamiccompromise or likely urgent intervention. However, manypatientsadmitted to the ICU stop bleeding and do not require further...